Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Cancer Experience Registry: An Online Research Study to Understand the Experiences of Cancer Patients and Caregivers
Conditions:   Neoplasms;   Cancer;   Caregiver
Intervention:  
Sponsor:   Cancer Support Community, Research and Training Institute, Philadelphia
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 22, 2022 / by / in
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Conditions:   HER2-positive Breast Cancer;   HER2-positive Gastric Cancer;   HER2-positive Colorectal Cancer;   HER2-expressing Non-small Cell Lung Cancer
Interventions:   Drug: SBT6050;   Drug: trastuzumab deruxtecan;   Drug: tucatinib;   Drug: trastuzumab;   Drug: capecitabine
Sponsor:   Silverback Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 20, 2022 / by / in
How Gas-Filled Intragastric Balloons or Endoscopic Sleeve Gastroplasty Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements
Condition:   Obesity
Interventions:   Device: GF-IGB: Obalon Balloon;   Dietary Supplement: Medically Supervised Meal Replacement Program: My New Weigh;   Procedure: Endoscopic sleeve gastroplasty: (ESG)
Sponsor:   University of Colorado, Denver
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 19, 2022 / by / in
ERAS® Guidelines Validation of CRS With or Without HIPEC
Condition:   Peritoneal Diseases
Interventions:   Other: Pre-ERAS® phase (current clinical practice);   Other: Post-ERAS® implementation phase
Sponsor:   Hospices Civils de Lyon
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 12, 2022 / by / in
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
Conditions:   Triple-negative Breast Cancer;   Non-squamous Non-small-cell Lung Cancer;   NSCLC;   Estrogen-receptor-positive Breast Cancer;   Progesterone-receptor-positive Breast Cancer;   Estrogen-receptor-negative Breast Cancer;   ER-negative Breast Cancer;   Progesterone-receptor Negative Breast Cancer;   PR-negative Breast Cancer;   HER2-negative Breast Cancer;   ER-positive Breast Cancer;   PR-positive Breast Cancer;   Platinum-resistant Ovarian Cancer;   Gastric Cancer;   Pancreatic Cancer
Intervention:   Drug: Zilovertamab vedotin
Sponsor:   VelosBio Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 22, 2021 / by / in
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Conditions:   Eosinophilic Gastritis;   Eosinophilic Duodenitis
Interventions:   Drug: AK002;   Other: Placebo
Sponsor:   Allakos, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 11, 2021 / by / in
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Conditions:   Advanced Solid Tumors;   Glioblastoma;   Soft Tissue Sarcoma (Excluding GIST);   Endometrial Carcinoma;   Epithelial Ovarian Carcinoma;   Mesothelioma;   Gastroenteropancreatic Neuroendocrine Tumor;   SCLC;   Gastric Carcinoma;   Pancreatic Adenocarcinoma;   Colorectal Carcinoma;   Neuroendocrine Tumors
Interventions:   Drug: Lurbinectedin;   Drug: Irinotecan
Sponsor:   PharmaMar
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 3, 2021 / by / in
Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Conditions:   Metastatic Esophageal;   Gastric Cancer;   Metastatic Head and Neck Carcinoma;   Metastatic Hepatocellular Carcinoma;   Metastatic HPV Related Solid Tumors;   Metastatic Ovarian Carcinoma;   Metastatic Soft Tissue Sarcoma;   Metastatic Uveal Melanoma
Interventions:   Drug: LVGN3616 + LVGN6051 + Nab-Paclitaxel;   Drug: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide;   Drug: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel;   Drug: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Sponsors:   M.D. Anderson Cancer Center;   Lyvgen Biopharma Holdings Limited
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 27, 2021 / by / in
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)
Conditions:   Oesophageal Squamous Cell Carcinoma;   Gastric Cancer;   Hepatocellular Carcinoma;   Colorectal Cancer
Interventions:   Drug: THOR-707;   Drug: Pembrolizumab;   Drug: Cetuximab
Sponsors:   Sanofi;   Merck Sharp & Dohme Corp.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 27, 2021 / by / in
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
Conditions:   Gastroesophageal Junction (GEJ) Cancers;   Advanced HNSCC
Interventions:   Drug: N-803;   Drug: Pembrolizumab;   Biological: PD-L1 t-haNK
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 20, 2021 / by / in